Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients
Barbara Testoni, Fanny Lebossé, Caroline Scholtès, et al.
Journal of Hepatology (2018) Vol. 70, Iss. 4, pp. 615-625
Open Access | Times Cited: 257

Showing 1-25 of 257 citing articles:

Therapeutic strategies for hepatitis B virus infection: towards a cure
Gregory Fanning, Fabien Zoulim, Jinlin Hou, et al.
Nature Reviews Drug Discovery (2019) Vol. 18, Iss. 11, pp. 827-844
Closed Access | Times Cited: 467
Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference‡
Markus Cornberg, Anna Suk‐Fong Lok, Norah A. Terrault, et al.
Journal of Hepatology (2019) Vol. 72, Iss. 3, pp. 539-557
Open Access | Times Cited: 292
A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook
Anna Kramvis, Kyong‐Mi Chang, Maura Dandri, et al.
Nature Reviews Gastroenterology & Hepatology (2022) Vol. 19, Iss. 11, pp. 727-745
Open Access | Times Cited: 117
Getting to HBV cure: The promising paths forward
Scott Fung, Hannah Choi, Adam J. Gehring, et al.
Hepatology (2022) Vol. 76, Iss. 1, pp. 233-250
Closed Access | Times Cited: 109
The scientific basis of combination therapy for chronic hepatitis B functional cure
Seng Gee Lim, Thomas F. Baumert, Carolina Boni, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 4, pp. 238-253
Open Access | Times Cited: 93
KASL clinical practice guidelines for management of chronic hepatitis B

Clinical and Molecular Hepatology (2022) Vol. 28, Iss. 2, pp. 276-331
Open Access | Times Cited: 89
HBx-Induced HSPA8 Stimulates HBV Replication and Suppresses Ferroptosis to Support Liver Cancer Progression
Yufei Wang, Man Zhao, Lina Zhao, et al.
Cancer Research (2023) Vol. 83, Iss. 7, pp. 1048-1061
Open Access | Times Cited: 64
Hepatitis B virus DNA integration: Implications for diagnostics, therapy, and outcome
Fabien Zoulim, Pei‐Jer Chen, Maura Dandri, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 6, pp. 1087-1099
Open Access | Times Cited: 17
Pregenomic HBV RNA and Hepatitis B Core‐Related Antigen Predict Outcomes in Hepatitis B e Antigen–Negative Chronic Hepatitis B Patients Suppressed on Nucleos(T)ide Analogue Therapy
Ivana Carey, Jeffrey Gersch, Bo Wang, et al.
Hepatology (2019) Vol. 72, Iss. 1, pp. 42-57
Closed Access | Times Cited: 142
Hepatitis B surface antigen seroclearance: Immune mechanisms, clinical impact, importance for drug development
Issam Tout, Dimitri Loureiro, Abdellah Mansouri, et al.
Journal of Hepatology (2020) Vol. 73, Iss. 2, pp. 409-422
Open Access | Times Cited: 128
Novel biomarkers for the management of chronic hepatitis B
Takako Inoue, Yasuhito Tanaka
Clinical and Molecular Hepatology (2020) Vol. 26, Iss. 3, pp. 261-279
Open Access | Times Cited: 113
High Level of Hepatitis B Core–Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load
Tai‐Chung Tseng, Chun‐Jen Liu, Chen-Yang Hsu, et al.
Gastroenterology (2019) Vol. 157, Iss. 6, pp. 1518-1529.e3
Open Access | Times Cited: 111
JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection
Fabien Zoulim, Oliver Lenz, Joris Vandenbossche, et al.
Gastroenterology (2020) Vol. 159, Iss. 2, pp. 521-533.e9
Open Access | Times Cited: 98
Targets and future direct-acting antiviral approaches to achieve hepatitis B virus cure
Tarik Asselah, Dimitri Loureiro, Nathalie Boyer, et al.
˜The œLancet. Gastroenterology & hepatology (2019) Vol. 4, Iss. 11, pp. 883-892
Closed Access | Times Cited: 92
Guidance for Design and Endpoints of Clinical Trials in Chronic Hepatitis B—Report From the 2019 EASL‐AASLD HBV Treatment Endpoints Conference
Markus Cornberg, Anna Suk‐Fong Lok, Norah A. Terrault, et al.
Hepatology (2019) Vol. 71, Iss. 3, pp. 1070-1092
Open Access | Times Cited: 89
Full-length 5'RACE identifies all major HBV transcripts in HBV-infected hepatocytes and patient serum
Bernd Stadelmayer, Audrey Diederichs, Fleur Chapus, et al.
Journal of Hepatology (2020) Vol. 73, Iss. 1, pp. 40-51
Open Access | Times Cited: 72
Viral hepatitis update: Progress and perspectives
María Belén Pisano, Cecilia Graciela Giadans, Diego Flichman, et al.
World Journal of Gastroenterology (2021) Vol. 27, Iss. 26, pp. 4018-4044
Open Access | Times Cited: 69
Impact of HBsAg and HBcrAg levels on phenotype and function of HBV-specific T cells in patients with chronic hepatitis B virus infection
Elmira Aliabadi, Melanie Urbanek‐Quaing, Benjamin Maasoumy, et al.
Gut (2021) Vol. 71, Iss. 11, pp. 2300-2312
Open Access | Times Cited: 68
Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB
Man‐Fung Yuen, Stephen Locarnini, Tien Huey Lim, et al.
Journal of Hepatology (2022) Vol. 77, Iss. 5, pp. 1287-1298
Open Access | Times Cited: 67
End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB
Da Huang, Di Wu, Peng Wang, et al.
Journal of Hepatology (2022) Vol. 77, Iss. 1, pp. 42-54
Open Access | Times Cited: 59
Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension
Elisabetta Degasperi, Maria Paola Anolli, Sara Uceda Renteria, et al.
Journal of Hepatology (2022) Vol. 77, Iss. 6, pp. 1525-1531
Closed Access | Times Cited: 51
Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection
Chih–Lin Lin, Jia‐Horng Kao
Clinical and Molecular Hepatology (2023) Vol. 29, Iss. 3, pp. 605-622
Open Access | Times Cited: 40
Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection
Harry L.A. Janssen, Jinlin Hou, Tarik Asselah, et al.
Gut (2023) Vol. 72, Iss. 7, pp. 1385-1398
Open Access | Times Cited: 36
New Perspectives on Development of Curative Strategies for Chronic Hepatitis B
Jordan J. Feld, Anna S. Lok, Fabien Zoulim
Clinical Gastroenterology and Hepatology (2023) Vol. 21, Iss. 8, pp. 2040-2050
Open Access | Times Cited: 31
Biomarkers of transfusion transmitted occult hepatitis B virus infection: Where are we and what next?
Michael X. Fu, Peter Simmonds, Monique Andersson, et al.
Reviews in Medical Virology (2024) Vol. 34, Iss. 2
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top